Gottlieb's quick goodbye triggers investor panic, biopharma bewilderment and at least one good riddance
admin 6th March 2019 Uncategorised 0FDA chief Scott Gottlieb will be gone within a month. Biotech investors are selling. Biopharma faces an uncharted regulatory landscape, with no idea which Gottlieb initiatives will survive his exit. Even Silicon Valley is mourning. And the big question is: Who’s
read more